Clinical Trials | CardiAI™

Clinical Trials

Our research division not only conducts various research studies to develop next generation biomedical diagnostics devices and software, but also participates in various national and international clinical trials of major pharmaceutical companies. Here are some of the clinical trials our company participates and provides support.

ACT STUDY

Anti-Coronavirus Therapies to prevent COVID-19 progression trial This study will evaluate anti-inflammatory and anti-thrombotic therapy to determine whether they prevent clinical progression of COVID-19 in outpatients and inpatients. 

XATOA

Xarelto + Acetylsalicylic Acid: Treatment patterns and outcomes in patients with Atherosclerosis. A non-interventional study. An Observational Study to observe the treatment patterns and outcomes in patients with Atherosclerosis. A non-Interventional study.

Brain AF

Blinded randomized trial of Anticoagulant to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation: is the blinded randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.

Aware AF

Atrial fibrillation screening and make screening sustainable. Aware AF is the study to screen the Atrial fibrillation with the help of 7 days Holter (CardioSTAT devices).

RAMP

Measurement of NT-proBNP for the diagnosis and assessment of congestive heart failure.

PARTHENON

Patient registry assessing effectiveness and safety of Heart failure treatment with LCZ696 across Canada: (Sacubitril/Valsartan) Angiotensin receptor neprilysin inhibitor: Treatment of Heart failure with reduced ejection fraction to reduce the incidence of cardiovascular death.

GOAL

Guideline oriented approach to lipid lowering in Canada. Study focused on patients with high LDL levels.

AbbVie, Inc. Protocol: M16-047

A Phase 3 Randomized, Placebo-Controlled, Double-Blind study to evaluate Upadacitinib in combination with Topical Corticosteroids in Adolescent and Adult subjects with moderate to severe Atopic Dermatitis.

AbbVie, Inc. Protocol: M16-813

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to evaluate Risankizumab in Adult and Adolescent subjects with moderate to severe Atopic Dermatitis.

UCB Biopharma SPRL Protocol: PS0007

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 years) including a single open-label Arm(6-11years) study to evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric study participants with moderate to severe Chronic Plaque Psoriasis (PSO)

Asana BioSciences, LLC. Protocol: ASN002AD-201-EXT

A Phase 2, Multicenter, Open-Label Extension study to evaluate the Long-Term Safety, Tolerability and Efficacy of ASN002 in subjects with moderate to severe Atopic Dermatitis.

ACS iii

North American Acute Coronary Syndrome (ACS) Reflective III Pilot. To give feedback to physicians on their post-ACS lipid-lowering management to support their decision-making and choice of therapies and thereby better achieve evidence-based,4,9 guideline-recommended10 management of post-ACS patients.

Bristol-Myers Squibb Protocol: IM011047

A Multi-Center, Randomized, Double Blind, Placebo- and Active Comparator-Controlled Please 3 study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in subjects with moderate-to-severe Plaque Psoriasis.

Bristol-Mayers Squibb Protocol: IM011075

An Open-Label, Multi-Center extension study to characterize the long-team safety and efficacy of BMS-986165 in subjects with moderate-to-severe Plaque Psoriasis.

AbbVie, Inc. Protocol: M16-045

A Please 3 Randomized, Placebo-Controlled, Double-Blind study to evaluate Upadacitinib in Adolescent and Adult subjects with moderate to severe Atopic Dermatitis.

AbbVie, Inc. Protocol: M16-046

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active controlled Study comparing the Safety and Efficacy of Upadacitinib to Dupilumab in adult subjects with moderate to severe Atopic Dermatitis.

AbbVie, Inc. Protocol: M16-766

A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded study of Risankizumab compared to Secukinumab for the treatment of adult subjects with moderate to severe Plaque Psoriasis who are candidates for Systemic Therapy.

Incyte Protocol: INCB 18424-306

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety study of Ruxolitinib Cream followed by an extension period in participants with Vitiligo.

Pfizer, Inc. Protocol: B7451037

A Phase 2A, Randomized, Double-Blind, Placebo, Parallel Group, Multi-Center study to investigate the mechanism of action of Abrocitinib Monotherapy in Adult participants with moderate-to-severe Atopic Dermatitis.

Eli Lilly and Company Protocol: l1F-MC-RHCD

Multicenter, Double-Blind, Randomized, Placebo-Controlled study to evaluate Safety, Tolerability, and Efficacy of lxekizumab in patients from 6 to Less than 18 years of age with moderate-to-severe Plaque Psoriasis.